| 摘要 |
<p>The invention relates to novel antibodies capable of binding specifically to the human Insulin-like Growth Factor-I Receptor (IGF-IR), in particular monoclonal of murine origin, chimeric and humanized as well as the amino and nucleic acid sequences coding for said antibodies. The invention also concerns the use of said antibodies as medicine for prophylactic and/or therapeutic treatments of cancers as well as methods or kit for diagnosis of diseases related to overexpression of the IGF-IR receptor. The invention further concerns products and/or compositions containing such antibodies combined with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or conjugates with toxins and their use for preventing and/or treating certain cancers.</p> |
